CALCIUM ACETATE | A203135 | INVAGEN PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Roxane Laboratories, Inc. v. Camber Pharmaceuticals, Inc. et al 1 patentANDA 77728, 203135calcium acetate | D.N.J. | 2014-06-25 | Terminated 2018-07-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.1733
per ea
Lowest NADAC/Unit
$0.1733
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 76282037702CALCIUM ACETATE 667 MG CAPSULE | $0.1733 | EA | Generic | — | 2026-06-17 |
| 69097086283CALCIUM ACETATE 667 MG CAPSULE | $0.1733 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.